

1624 #3
2/28/01
82

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on **December 29, 2000**

Name: **C. Fong**

By: *C. Fong*

RECEIVED
JAN 23 2001
TECH CENTER 1600/2300

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re application of:

Gary D. GLICK, et al.

Application Serial No. 09/140790

Filed: November 8, 2000

For: **THERAPEUTIC APPLICATIONS
OF PRO-APOPTOTIC
BENZODIAZEPINES**



Art Unit: Unassigned

Examiner: Unassigned

Attorney's Docket No. 128019-203801

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been

RECEIVED
JAN 23 2001
PTO/PC/CS

cited by or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

Applicants have checked the appropriate boxes below.

- ☒ 1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No statement under 37 C.F.R. § 1.97(e) or fee is required.
- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
 - ☐ a. I hereby state that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
 - ☐ b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
 - ☐ c. Attached is our Check No. _____ in the amount of \$ _____ in payment of the fee under 37 C.F.R. § 1.17(p).
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. It is hereby requested that the Information Disclosure Statement be considered. Attached is our Check No. _____ in the amount of \$ _____ in payment of the fee under 37 C.F.R. § 1.17(i).
 - ☐ a. I hereby state that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
 - ☐ b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable

inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).

- TECH CENTER 1600 2300
JAN 23 2001
RECEIVED
- ☐ 4. Relevance of the non-English language document(s) is discussed in the present specification.
 - ☐ 5. The document(s) was/were cited in a corresponding foreign application. An English language version of the foreign search report is attached for the Examiner's information.
 - ☐ 6. A concise explanation of the relevance of the non-English language document(s) appears below:
 - ☐ 7. The Examiner's attention is directed to co-pending U.S. Patent Application No. _____, filed _____, which is directed to related technical subject matter. The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to that application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.
 - ☐ 8. Copies of the documents were cited by or submitted to the Office in Application No. _____, filed _____, which is relied upon for an earlier filing date under 35 S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 50-0974.

Respectfully submitted,


Antoinette F. Konski (Reg. No. 34,202)

Date: December 29, 2000

Baker & McKenzie
660 Hansen Way
Palo Alto, California 94304
(650) 856-2400

Form PTO-1449

Attorney's Docket No. 128019-203801

Application Serial No. 09/700,101

INFORMATION DISCLOSURE STATEMENT

Applicant(s)

Gary D. GLICK, et al.

(use several sheets if necessary)

Filing Date: November 8, 2000

Group Art Unit: Unassigned

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
	1.	02/28/1978	4,076,823	Wade, et al.			
	2.	08/29/1978	4,110,337	Szarvasi			
	3.	01/22/1985	4,495,101	Klaubert, et al.			
	4.	06/14/1988	4,751,223	Glamkowski, et al.			
	5.	08/20/1991	5,041,438	Hsu			
	6.	06/28/1994	5,324,726	Bock, et al.			
	7.	01/28/1997	5,597,915	Chambers, et al.			
	8.	07/07/1998	5,776,946	McGeer, et al.			
	9.	01/19/1999	5,861,380	Gyorkos, et al.			
	10.	12/21/1999	6,004,942	Firestein, et al.			
	11.	06/27/2000	6,080,588	Glick			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation	
							YES	NO
	12.	06/04/2000	WO 00/19200	PCT				

OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)

Examiner Initials	Ref. No.	Title
	13.	Adachi, M., et al., "Aberrant Transcription Caused by the Insertion of an Early Transposable Element in an Intron of the Fas Antigen Gene of <i>lpr</i> Mice," <i>Proc. Natl. Acad. Sci. USA</i> - 90:1756-1760 (1993) ✓
	14.	Adelman, N.E., et al., "Treatment of (NZB X NZW) _{F1} Disease with Anti-I-A Monoclonal Antibodies," <i>J. Exp. Med.</i> - 158:1350-1355 (1983) ✓
	15.	Baader, S.L., et al., "Uptake and Cytotoxicity of Ascorbic Acid and Dehydroascorbic Acid in Neuroblastoma (SK-N-SH) and Neuroectodermal (SK-N-LO) Cells," <i>Anticancer Research</i> - 14:221-228 (1994) ✓
	16.	Beale, P.J., et al., "BCL-2 Family Protein Expression and Platinum Drug Resistance in Ovarian Carcinoma," <i>British Journal of Cancer</i> - 82(2):436-440 (2000) ✓
	17.	Boojamra, C.G., et al., "Solid-Phase Synthesis of 1,4-Benzodiazepine-2,5-Diones. Library Preparation and Demonstration of Synthesis Generality," <i>J. Org. Chem.</i> - 62:1240-1256 (1997) ✓
	18.	Bunin, B.A., et al., "A General and Expedient Method for the Solid-Phase Synthesis of 1,4-Benzodiazepine Derivatives," <i>J. Am. Chem. Soc.</i> - 114:10997-10998 (1992) ✓
	19.	Bunin, B.A., et al., "The Combinatorial Synthesis and Chemical and Biological Evaluation of a 1,4-Benzodiazepine Library," <i>Proc. Natl. Acad. Sci. USA</i> - 91:7408-4712 (1994) ✓
	20.	Chumakov, A.M., et al., "Analysis of p53 Transactivation Through High-Affinity Binding Sites," <i>Oncogene</i> - 8:3005-3011 (1993) ✓
	21.	Cohen, P.L., et al., " <i>Lpr</i> and <i>gld</i> : Single Gene Models of Systemic Autoimmunity and Lymphoproliferative Disease," <i>Annu. Rev. Immunol.</i> - 9:243-269 (1991) ✓
	22.	Crabtree, R.H., "A New Type of Hydrogen Bond," <i>Science</i> - 282:2000-2001 (1998) ✓
	23.	Desoize, B., "Anticancer Drug Resistance and Inhibition of Apoptosis," <i>Anticancer Research</i> - 14:2291-2294 (1994) ✓

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance. Include a copy of this form with next communication to applicant.

154157.1

193696v1

Form PTO-1449	Attorney's Docket No. 128019-203801	Application Serial No. 102700,101
INFORMATION DISCLOSURE STATEMENT	Applicant(s) Gary D. GLICK, et al.	
(use several sheets if necessary)	Filing Date: November 8, 2000	Group Art Unit: Unassigned

OTHER DOCUMENTS (Continuation)

(including author, title, date, pertinent pages, etc.)

- | | |
|-----|--|
| 24. | Doble, A., et al., "Labelling of Peripheral-Type Benzodiazepine Binding Sites in Human Brain with [³ H]PK 11195: Anatomical and Subcellular Distribution," <i>Brain Research Bulletin</i> - 18:49-61 (1987) |
| 25. | Donadio, J.V., et al., "Immunosuppressive Drug Therapy in Lupus Nephritis," <i>American Journal of Kidney Diseases</i> - 21(3):239-250 (1993) |
| 26. | Ermak, T.H., et al., "Treatment of Murine Lupus with Monoclonal Antibody to L3T4," <i>Laboratory Investigation</i> - 61(4):447-456 (1989) |
| 27. | Gallant, J.E., et al., "Incidence and Natural History of Cytomegalovirus Disease in Patients with Advanced Human Immunodeficiency Virus Disease Treated with Zidovudine," <i>The Journal of Infectious Diseases</i> - 166:1223-1227 (1992) |
| 28. | Garcia-Calvo, M., et al., "Inhibition of Human Caspases by Peptide-Based and Macromolecular Inhibitors," <i>The Journal of Biological Chemistry</i> - 273(49):32608-32613 (1998) |
| 29. | Gorczyca, W., et al., "Induction of DNA Strand Breaks Associated with Apoptosis During Treatment of Leukemias," <i>Leukemia</i> - 7(5):659-670 (1993) |
| 30. | Gordon, C., et al., "Chronic Therapy with Recombinant Tumor Necrosis Factor- α in Autoimmune NZB/NZW F ₁ Mice," <i>Clinical Immunology and Immunopathology</i> - 52:421-434 (1989) |
| 31. | Gordon, E.M., et al., "Applications of Combinatorial Technologies to Drug Discovery. 2. Combinatorial Organic Synthesis, Library Screening Strategies, and Future Directions," <i>Journal of Medicinal Chemistry</i> - 37(10):1385-1401 (1994) |
| 32. | Hahn, B.H., et al., "Influence of Cyclophosphamide and Other Immunosuppressive Drugs on Immune Disorders and Neoplasia in NZB/NZW Mice," <i>Arthritis and Rheumatism</i> - 18(2):145-152 (1975) |
| 33. | Hang, L., et al., "A Spontaneous Rheumatoid Arthritis-Like Disease in MRL/l Mice," <i>J. Exp. Med.</i> - 155:1690-1701 (1982) |
| 34. | Horowitz, R.E., et al., "Cyclophosphamide Treatment of Mouse Systemic Lupus Erythematosus," <i>Laboratory Investigation</i> - 21(3):199-206 (1969) |
| 35. | Itoh, N., et al., "The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis," <i>Cell</i> - 66:233-243 (1991) |
| 36. | Koopman, W.J., et al., "The MRL-lpr/lpr Mouse. A Model for the Study of Rheumatoid Arthritis," <i>Scand. J. Rheumatology - Suppl</i> 75:284-289 (1988) |
| 37. | Korsmeyer, S.J., "Bcl-2 Initiates a New Category of Oncogenes: Regulators of Cell Death," <i>Blood</i> - 80(4):879-886 (1992) |
| 38. | Liu, J.R., et al., "Bcl-x _L is Expressed in Ovarian Carcinoma and Modulates Chemotherapy-Induced Apoptosis," <i>Gynecologic Oncology</i> - 70:398-403 (1998) |
| 39. | Los, M., et al., "The Role of Caspases in Development, Immunity, and Apoptotic Signal Transduction: Lessons from Knockout Mice," <i>Immunity</i> - 10:629-639 (1999) |
| 40. | Luria, et al., "General Virology - 3 rd edition, pp. 436-446 (1978) - Eds. John Wiley & Sons, New York |
| 41. | Marino, M., et al., "Prevention of Systemic Lupus Erythematosus in MRL/lpr Mice by Administration of an Immunoglobulin-Binding peptide," <i>Nature Biotechnology</i> - 18:735-739 (2000) |
| 42. | McDonnell, T.J., et al., "Progression from Lymphoid Hyperplasia to High-Grade Malignant Lymphoma in Mice Transgenic for the t(14;18)," <i>Nature</i> - 349:254-256 (1991) |
| 43. | Nagata, S., "Human Autoimmune Lymphoproliferative Syndrome, a Defect in the Apoptosis-Inducing Fas Receptor: A Lesson from the Mouse Model," <i>J. Hum. Genet.</i> - 43:2-8 (1998) |
| 44. | Okuyama, H., et al., "Analysis of Defective Delayed-Type Hypersensitivity in Autoimmune Mice Bearing lpr Gene," <i>Clin. Exp. Immunol.</i> - 63:87-94 (1986) |
| 45. | Okuyama, H., et al., "Effect of Cyclophosphamide Pretreatment on Defective Delayed-Type Hypersensitivity in Autoimmune-Prone MRL Mice," <i>Int. Arch. Allergy Appl. Immunol.</i> - 88:394-401 (1989) |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformity. Include a copy of this form with next communication to applicant.

154157.1

193696v1

Form PTO-1449	Attorney's Docket No. 128019-203801	Application Serial No. 09/700,101
INFORMATION DISCLOSURE STATEMENT	Applicant(s) Gary D. GLICK, et al.	
(use several sheets if necessary)	Filing Date: November 8, 2000	Group Art Unit: Unassigned

OTHER DOCUMENTS (Continuation)
(including author, title, date, pertinent pages, etc.)

- | | |
|-----|--|
| 46. | Ozols, R.F., "Paclitaxel Plus Carboplatin in the Treatment of Ovarian Cancer," <i>Seminars in Oncology</i> - 26(1)(Supp. 2):84-89 (1999) ✓ |
| 47. | Pestell, K.E., et al., "Characterisation of the P53 Status, BCL-2 Expression and Radiation and Platinum Drug Sensitivity of a Panel of Human Ovarian Cancer Cell Lines," <i>Int. J. Cancer</i> - 77:913-918 (1998) ✓ |
| 48. | Raynaud, F.I., et al., "Intracellular Metabolism of the Orally Active Platinum Drug JM216: Influence of Glutathione Levels," <i>Br. J. Cancer</i> - 74(3):380-386 (1996) ✓ |
| 49. | Russell, J.H., et al., "Mature T Cells of Autoimmune <i>lpr/lpr</i> Mice have a Defect in Antigen-Stimulated Suicide," <i>Proc. Natl. Acad. Sci. USA</i> - 90:4409-4413 (1993) ✓ |
| 50. | Sakata, K., et al., "Role of Fas/FasL Interaction in Physiology and Pathology: The Good and the Bad," <i>Clinical Immunology and Immunopathology</i> - 87(1):1-7 (1998) ✓ |
| 51. | Sandstrom, P.A., et al., "Autocrine Production of Extracellular Catalase Prevents Apoptosis of the Human CEM T-Cell Line in Serum-Free Medium," <i>Proc. Natl. Acad. Sci. USA</i> - 90:4708-4712 (1993) ✓ |
| 52. | Schoemaker, H., et al., "Specific High-Affinity Binding Sites for [³ H]Ro5-4864 in Rat Brain and Kidney," <i>The Journal of Pharmacology and Experimental Therapeutics</i> - 225(1):61-69 (1983) ✓ |
| 53. | Schwab, M., et al., "Amplified DNA with Limited Homology to <i>myc</i> Cellular Oncogene is Shared by Human Neuroblastoma Cell Lines and a Neuroblastoma Tumour," <i>Nature</i> - 305:245-248 (1983) ✓ |
| | Scott, C.F., et al., "Comparison of Antigen-Specific T Cell Responses in Autoimmune MRL/mp- <i>lpr/lpr</i> and MRL/Mp- <i>+/-</i> Mice," <i>The Journal of Immunology</i> - 132(2):633-639 (1984) ✓ |
| 55. | Sentman, C.L., et al., "bcl-2 Inhibits Multiple Forms of Apoptosis but not Negative Selection in Thymocytes," <i>Cell</i> - 67:879-888 (1991) ✓ |
| 56. | Sheppard, R.C., et al., "Acid-Labile Resin Linkage Agents for Use in Solid Phase Peptide Synthesis," <i>Int. J. Peptide Protein Res.</i> - 20:451-454 (1982) ✓ |
| 57. | Stevens, S.Y., et al., "Non Nucleic Acid Inhibitors of Protein-DNA Interactions Identified Through Combinatorial Chemistry," <i>J. Am. Chem. Soc.</i> - 118:10650-10651 (1996) ✓ |
| 58. | Sugimoto, T., et al., "Determination of Cell Surface Membrane Antigens Common to Both Human Neuroblastoma and Leukemia-Lymphoma Cell Lines by a Panel of 38 Monoclonal Antibodies," <i>JNCI</i> - 73(1):51-57 (1984) ✓ |
| 59. | Swanson, P.C., et al., "High Resolution Epitope Mapping of an Anti-DNA Autoantibody Using Model DNA Ligands," <i>J. Immunology</i> - 152(5):2601-2612 (1994) ✓ |
| 60. | Swanson, P.C., et al., "Ligand Recognition by Murine Anti-DNA Autoantibodies," <i>J. Clin. Invest.</i> - 97(7):1748-1760 (1996) ✓ |
| 61. | Takahashi, T., et al., "Generalized Lymphoproliferative Disease in Mice, Caused by a Point Mutation in the Fas Ligand," <i>Cell</i> - 76:969-976 (1994) ✓ |
| 62. | Theofilopoulos, A.N., et al., "Murine Models of Systemic Lupus Erythematosus," <i>Advances in Immunology</i> - 37:269-390 (1985) ✓ |
| 63. | Thompson, C.B., "Apoptosis in the Pathogenesis and Treatment of Disease," <i>Science</i> - 267:1456-1462 (1995) ✓ |
| 64. | Watanabe-Fukunaga, R., et al., "Lymphoproliferation Disorder in Mice Explained by Defects in Fas Antigen that Mediates Apoptosis," <i>Nature</i> - 356:314-317 (1992) ✓ |
| 65. | White, E., "Life, Death, and the Pursuit of Apoptosis," <i>Genes & Development</i> - 10:1-15 (1996) ✓ |
| 66. | Wu, G.Y., et al., "Receptor-Mediated <i>in Vitro</i> Gene Transformation by a Soluble DNA Carrier System," <i>The Journal of Biological Chemistry</i> - 262(10):4429-4432 (1987) ✓ |
| 67. | Wyllie, A.H., "The Genetic Regulation of Apoptosis," <i>Current Opinion in Genetics & Development</i> - 5:97-104 (1995) ✓ |
| 68. | Zamzami, N., et al., "Mitochondrial Control of Nuclear Apoptosis," <i>J. Exp. Med.</i> - 183:1533-1544 (1996) |
| 69. | Zoratti, M., et al., "The Mitochondrial Permeability Transition," <i>Biochimica et Biophysica Acta</i> - 1241:139-176 (1995) |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformity. Include a copy of this form with next communication to applicant.

154157.1

193696v1